Literature DB >> 12926978

Optimal treatment of pyoderma gangrenosum.

Samuel Gettler1, Marti Rothe, Caron Grin, Jane Grant-Kels.   

Abstract

The optimal treatment of pyoderma gangrenosum includes a combination of local wound care and systemic medications. Oral and pulse intravenous corticosteroids have traditionally been the most commonly recommended first-line systemic therapies. Cyclosporine, with or without corticosteroids, has more recently emerged as a first-line systemic treatment. A multitude of immunosuppressive and immune-modulating medications, as well as antimicrobial agents with anti-inflammatory properties have also been widely prescribed. Often, it is difficult to achieve control of aggressive cases of pyoderma gangrenosum, necessitating administration of a combination of systemic therapies. Furthermore, patients recalcitrant to one or many medications are frequently reported. Concomitant disease, intolerance to a class of medications, and the patient's response to prior therapies can help guide a practitioner in choosing the optimal treatment of pyoderma gangrenosum.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12926978     DOI: 10.2165/00128071-200304090-00002

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  9 in total

1.  Violaceous-rimmed ulcers.

Authors:  Cindy Berthelot; Jennifer Clay Cather
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-04

2.  [Chronic fistulas with impaired wound healing].

Authors:  A Feser; G Schuler; M Simon; M Lüftl
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

3.  Disseminated refractory pyoderma gangraenosum during an ulcerative colitis flare. Treatment with infliximab.

Authors:  Vasiliki A Zampeli; Undine Lippert; Georgios Nikolakis; Evgenia Makrantonaki; Thrasivoulos G Tzellos; Ulf Krause; Christos C Zouboulis
Journal:  J Dermatol Case Rep       Date:  2015-09-30

Review 4.  Pyoderma gangrenosum treated with high-dose intravenous immunoglobulins: Two cases and review of the literature.

Authors:  Nicolas Meyer; Valérie Ferraro; Marie-Henriette Mignard; Henri Adamski; Jacqueline Chevrant-Breton
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

5.  Staged correction of an equinovarus deformity due to pyoderma gangrenosum using a Taylor spatial frame and tibiotalar calcaneal fusion with an intramedullary device.

Authors:  Jaime L Bellamy; Courtney A Holland; Mark Hsiao; Joseph R Hsu
Journal:  Strategies Trauma Limb Reconstr       Date:  2011-08-24

6.  Pyoderma gangrenosum following complex reconstruction of a large-scale lower limb defect by combined Parascapular and latissimus dorsi flap.

Authors:  Tomke Cordts; Amir K Bigdeli; Leila Harhaus; Christoph Hirche; Thomas Kremer; Ulrich Kneser; Volker J Schmidt
Journal:  J Surg Case Rep       Date:  2017-01-17

Review 7.  [Acute lymphoblastic leukemia complicated with pyoderma gangrenosum: a case report and literatures review].

Authors:  X Shi; Z G Cui; F Hou; H Xu; H Wang; Z Su; H G Zhao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-04-14

8.  Peritoneal Dialysis Exit Site Pyoderma Gangrenosum: A Case Report.

Authors:  Salman Anwar; Karen Holfeld; Bhanu Prasad
Journal:  Case Rep Nephrol Dial       Date:  2018-11-14

Review 9.  Recurrent pyoderma gangrenosum precipitated by breast cancer: a case report and review of the literature.

Authors:  Renata Duchnowska; Ewa Ziajka; Agnieszka Góralska; Bartłomiej Grala
Journal:  J Med Case Rep       Date:  2014-06-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.